key: cord-0014985-d7tvfqmn
authors: Davis, Owen K.; Rosenwaks, Zev
title: Primum non nocere: in vitro fertilization in the epicenter
date: 2020-07-09
journal: Fertil Steril
DOI: 10.1016/j.fertnstert.2020.06.011
sha: 6844f10a5d6642db699bf6860a058ab1dfa71c52
doc_id: 14985
cord_uid: d7tvfqmn

nan

The world is in the throes of a pandemic on a scale unprecedented since the H1N1 flu pandemic of 1918-1919, which infected an estimated 500 million people worldwide and resulted in over 50 million deaths, approximately 675,000 of those in the United States. COVID-19 is a respiratory illness with a potentially multisystemic clinical impact caused by the novel coronavirus SARS-CoV-2, an enveloped, single-strand RNA virus. The current pandemic, as of this writing, has infected close to 6 million individuals worldwide with over 360,000 deaths. In the United States we have thus far documented close to 1.8 million cases and suffered over 100,000 deaths due to this virus.

New York rapidly became the epicenter of our national health crisis with over 360,000 confirmed cases and more than 23,000 attributed deaths as of this point. At the peak of the initial wave of this epidemic, New York experienced a daily mortality rate that approached 800 in early April of this year; the exponential growth of this crisis is underscored by the fact that the first confirmed infection in New York City was on March 11, 2020. The acute vulnerability of New York was likely due to a number of factors including its population density, the high infectivity rate of this particular virus, and the city's status as a major hub for international travel. In essence, the genesis of this local and ultimately national epidemic was ''airborne'' both literally and figuratively; preliminary genetic analysis of the causative virus suggests that its origins were predominantly from Europe.

It is undeniable that our health care infrastructure was unprepared to cope nimbly with this global threat due to deficiencies in the availability and scale of accurate testing, in medical supplies ranging from personal protective equipment (PPE) to mechanical ventilators, in the total local and national numbers of hospital and intensive care beds, and in the requisite specialized personnel. As a consequence, health systems in the United States have been stretched almost to the breaking point. In New York, by executive order, hospitals were required to suspend elective procedures and to increase their inpatient capacity by 50% in a miniscule time frame. Field hospitals were constructed, hospital wards and operating rooms were repurposed as intensive care units, and personnel were redeployed from their normal medical responsibilities to the care of critically ill COVID-19 patients.

In response to this explosive health crisis, the American Society for Reproductive Medicine assembled a Coronavirus/ COVID-19 task force that promulgated a set of recommendations pertinent to the practice of reproductive medicine during the pandemic (1). It was stressed at the outset that this guidance would be a dynamic and iterative process, given the fluid nature of the crisis. The initial guidelines were published on March 17 of this year, with four subsequent updates as of this writing. In brief, one of the core recommendations in the initial document, published while the nation was on the sharply ascending limb of the epidemic, was to suspend the initiation of new treatment cycles including ovulation induction, in vitro fertilization (IVF), and nonurgent fertility preservation procedures. The initial issuance of this guidance was met with a disingenuous backlash from some quarters of the assisted reproduction technology (ART) professional community, who suggested that such restraint would diminish the perceived importance of fertility care, further intimating that our patients are predominantly healthy young women who comprise a less susceptible and lower risk population vis-a-vis the risks of COVID-19.

At Weill Cornell Medicine's Center for Reproductive Medicine, we proactively pursued an aggressive policy of risk mitigation due to several salient concerns. First, given the clear evidence for pervasive person-to-person spread, patient travel (in some cases via mass transit) to an ART practice would entail an increased risk of community-acquired infection. Second, waiting rooms, consultations, and clinical examinations and procedures expose patients to each other and to clinical staff, all in an indoor setting. Third, female gender and relative youth does not in fact confer absolute protection from the ravages of this virus; a significant number of critically ill patients requiring mechanical ventilation, including many who died, have been in their 30s and 40s, with some in their 20s.

Additionally, given estimates that anywhere from 30% to 80% of infected individuals may be asymptomatic shedders, it is clear that acquisition of the virus poses a significant risk to other family members (particularly the elderly) and indeed to the community at large. Fourth, there is much that we do not yet know about the maternal and fetal risks of COVID-19 in pregnancy, especially with infection in the first and second trimester; although the possibility of vertical transmission is not established, current data are inconclusive (2) . It is reassuring that maternal susceptibility and mortality risks appear to be lower than what was experienced with SARS and MERS, but the experience with this novel and unique coronavirus is limited, and our knowledge is evolving.

Finally, the normal practice of ART consumes resources that were in critically short supply during the initial onslaught and peaking of the epidemic, ranging from PPE to anesthesia machines to personnel, such as anesthesiologists who were redeployed to critical care. Several members of our clinical team were redeployed to fulfill frontline functions in our hospital system, running the gamut from screening to telehealth, inpatient floor care, and intensive care units (ICUs).

During the rise, peak, and plateau of the crisis we suspended all IVF and ovulation induction starts with the exception of urgent fertility preservation cycles (oncofertility), and converted our practices to telemedicine-based platforms, with the exception of emergency procedures. Fortunately, major milestones have been attained in New York with regard to decreasing COVID-19-related hospitalizations, ICU occupancy, and death rates. This abatement is allowing the cautious, graduated resumption of other vital non-COVID medical and surgical activities across the medical center. However, the virus is an ever-present threat, pending the development and widespread availability of effective pharmacologic therapies and/or an effective vaccine.

As we resume our reproductive medicine and ART activities at our center, we have put several risk-mitigation strategies into place. All equipment and surfaces are disinfected before and after each patient encounter. Hand sanitizer is readily accessible to all patients and personnel at multiple stations. Given the critical role of ''social distancing,'' we are endeavoring to limit the absolute numbers and density of patients and health care providers occupying our physical spaces in addition to requiring face masks for all patients and personnel.

Patient registration is performed online, we have halved the number of seats in our waiting rooms, we are capping the daily number of ART cycle starts substantially below our accustomed volume, and we are delaying starts if that limit is reached (with oral contraceptives and estradiol patches). Patients are assigned specific time slots for monitoring appointments, and they are, with few exceptions, not permitted to bring a companion/partner to their visits. We have started monitoring visits earlier in the day, and we have opened one of our satellite offices for additional weekend monitoring to minimize the number of patients coming to our center's main office.

The number of staff in the clinical facilities and embryology laboratory have been reduced through shifts. Individual physicians' practice office hours use telemedicine wherever possible, and in-office patient visits, where necessary, are scheduled to occur only after the morning monitoring has been completed. We have devised a point system, which weights the likely duration of various types of patient visits (e.g., four points for an initial consultation, one point for an ultrasound examination, etc.), and we have strictly limited the number of points/hour that physicians can schedule into their office hours. Oocyte retrievals and embryo transfers have been spaced further apart to minimize the number of patients in the ambulatory surgery waiting room and postanesthesia care unit.

We have also implemented several screening and testing procedures. In addition to questionnaires about possible exposure and symptomatology and temperature checks when patients arrive, we have instituted a system of COVID-19 nucleic acid testing via nasopharyngeal swab/polymerase chain reaction (PCR) for all patients at the planned start of their IVF cycles, with repeat testing within 72 hours before their oocyte retrievals (a hospital policy for all operative procedures). We have adopted a more uniform use of preretrieval gonadotropin-releasing hormone agonist triggers, where applicable, to further minimize any risk for ovarian hyperstimulation syndrome (OHSS), given the unknown ramifications of even mild or moderate OHSS in the setting of a newly acquired infection with COVID-19, including concerns regarding hypercoagulability (3).

We have ensured that all patients are counseled regarding our COVID-era policies, procedures, and precautions including scheduling, testing, and the possibility that a cycle start will be delayed or an oocyte retrieval canceled should the COVID-19 PCR indicate an infection. We specifically advise our patients on the potential maternal-fetal-neonatal risks of COVID infection and emphasize that there is much that we do not yet know, especially with regard to early pregnancy exposure and potential risks later in pregnancy.

The COVID-19 pandemic has wrought massive damage worldwide, most importantly with respect to human suffering and death. It has led to a reactive upending of many of our social norms, in addition to unprecedented upheaval in national and global economies. Given that natural herd immunity is not on the horizon, the virus poses an ongoing threat poised to explode anew absent extraordinary preventive efforts, which at this point focus on testing and isolation, strict hand hygiene, the use of face masks, and social distancing. With luck, we will have an effective vaccine in the not too distant future. As we resume our vital work of helping our patients create and grow their families, it is critical that we do so as safely as possible, with an eye to minimizing risk. You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/users/16110-fertilityand-sterility/posts/30725

Patient management and clinical recommendations during the coronavirus (COVID-19) pandemic. Updates through

Possible vertical transmission of SARS CoV-2 from an infected mother to her newborn

Coronavirus disease 2019 in pregnancy: consider thromboembolic disorders and thromboprophylaxis